Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Research & Development (2016 - 2025)

CytomX Therapeutics' Research & Development history spans 12 years, with the latest figure at $21.2 million for Q4 2025.

  • For Q4 2025, Research & Development rose 43.58% year-over-year to $21.2 million; the TTM value through Dec 2025 reached $68.7 million, down 17.57%, while the annual FY2025 figure was $68.7 million, 17.57% down from the prior year.
  • Research & Development reached $21.2 million in Q4 2025 per CTMX's latest filing, up from $15.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $36.6 million in Q4 2021 to a low of $13.3 million in Q2 2025.
  • Average Research & Development over 5 years is $22.8 million, with a median of $21.3 million recorded in 2024.
  • The largest YoY upside for Research & Development was 66.22% in 2021 against a maximum downside of 47.75% in 2021.
  • A 5-year view of Research & Development shows it stood at $36.6 million in 2021, then tumbled by 46.52% to $19.6 million in 2022, then dropped by 0.91% to $19.4 million in 2023, then fell by 23.71% to $14.8 million in 2024, then skyrocketed by 43.58% to $21.2 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Research & Development are $21.2 million (Q4 2025), $15.3 million (Q3 2025), and $13.3 million (Q2 2025).